Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Dow
Medtronic
Baxter
AstraZeneca

Last Updated: August 15, 2022

Investigational Drug Information for Antineoplaston A10


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Antineoplaston A10?

Antineoplaston A10 is an investigational drug.

There have been 55 clinical trials for Antineoplaston A10. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2022.

The most common disease conditions in clinical trials are Central Nervous System Neoplasms, Nervous System Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are Burzynski Research Institute and [disabled in preview].

There are two hundred and forty US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Antineoplaston A10
TitleSponsorPhase
Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem GliomaBurzynski Research InstitutePhase 3
Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem GliomaBurzynski Research InstitutePhase 3
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's MacroglobulinemiaBurzynski Research InstitutePhase 2

See all Antineoplaston A10 clinical trials

Clinical Trial Summary for Antineoplaston A10

Top disease conditions for Antineoplaston A10
Top clinical trial sponsors for Antineoplaston A10

See all Antineoplaston A10 clinical trials

US Patents for Antineoplaston A10

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Antineoplaston A10 See Plans and Pricing Synergistic compositions for treating microbial infections University of Rochester (Rochester, NY) Temple University--Of the Commonwealth System of Higher Education (Philadelphia, PA) See Plans and Pricing
Antineoplaston A10 See Plans and Pricing Combination methods for treating cancers Gilead Sciences, Inc. (Foster City, CA) See Plans and Pricing
Antineoplaston A10 See Plans and Pricing Phosphatidylinositol 3-kinase inhibitors Gilead Sciences, Inc. (Foster City, CA) See Plans and Pricing
Antineoplaston A10 See Plans and Pricing Crystalline forms of tyrosine kinase inhibitors and their salts Purdue Pharma, L.P. (Stamford, CT) See Plans and Pricing
Antineoplaston A10 See Plans and Pricing Securinine and norsecurinine analogue compounds for the treatment of myeloid disorders CASE WESTERN RESERVE UNIVERSITY (Cleveland, OH) See Plans and Pricing
Antineoplaston A10 See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
Antineoplaston A10 See Plans and Pricing Multi-component nanochains Case Western Reserve University (Cleveland, OH) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Antineoplaston A10

Drugname Country Document Number Estimated Expiration Related US Patent
Antineoplaston A10 Australia AU2015339039 2034-10-31 See Plans and Pricing
Antineoplaston A10 Canada CA2965839 2034-10-31 See Plans and Pricing
Antineoplaston A10 China CN107106533 2034-10-31 See Plans and Pricing
Antineoplaston A10 European Patent Office EP3212183 2034-10-31 See Plans and Pricing
Antineoplaston A10 Japan JP2017538675 2034-10-31 See Plans and Pricing
Antineoplaston A10 Japan JP6590924 2034-10-31 See Plans and Pricing
Antineoplaston A10 World Intellectual Property Organization (WIPO) WO2016070021 2034-10-31 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Dow
Medtronic
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.